Respicardia
Developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health.
Launch date
Employees
Market cap
-
Enterprise valuation
€213—319m (Dealroom.co estimates Dec 2017.)
Minnetonka Minnesota (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $2.0m | Convertible | |
| N/A | $20.0m | Late VC | |
$5.1m | Debt | ||
$58.5m | Late VC | ||
N/A | Acquisition | ||
| Total Funding | €131m | ||
Related Content
Recent News about Respicardia
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.